Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis - ODIXa-DVT

Description:

The goal of the trial was to evaluate treatment with rivaroxaban, an oral, direct factor Xa inhibitor, compared with enoxaparin for treatment of proximal deep-vein thrombosis (DVT) among patients with acute symptomatic DVT.